Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionCreative Planning
Latest Disclosed Ownership24,122 shares
Latest Disclosed Value $ 7,981,312
Creative Planning reports 1.29% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 12, 2026 - Creative Planning filed a 13F-HR form disclosing ownership of 24,122 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $6,891,655 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 23,815 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 1.29% during the quarter. The current value of the position is $6,073,920 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,122 307 1.29 7,981 -15.72 0.0053
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,815 953 4.17 9,470 -9.15 0.0068
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,862 7,282 46.74 10,425 105.20 0.0080
2025-08-08 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,580 -519 -3.22 5,081 16.86 0.0043
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,099 5,286 48.89 4,347 70.87 0.0041
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,813 801 8.00 2,544 -7.59 0.0025
2024-10-11 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,012 1,978 24.62 2,754 41.03 0.0027
2024-08-15 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,034 3,110 63.16 1,952 165.58 0.0021
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,924 -148 -2.92 736 -24.23 0.0008
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,072 951 23.08 971 33.06 0.0018
2023-11-16 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,121 -835 -16.85 730 -22.53 0.0010
2023-07-21 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,956 1,379 38.55 941 31.42 0.0013
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,577 314 9.62 717 -7.61 0.0010
2023-02-10 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,263 676 26.13 775 49.61 0.0012
2022-11-03 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,587 62 2.46 518 40.76 0.0009
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,525 1,146 83.10 368 63.56 0.0006
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,379 -337 -19.64 225 -22.68 0.0003
2022-02-11 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,716 248 16.89 291 5.05 0.0005
2021-11-10 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,468 1,468 277 0.0005
2019-11-01 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -21,194 -100.00 0 -100.00
2019-07-26 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,194 21,194 1,538 0.0052
2017-10-17 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,045 -100.00 0 -100.00
2017-07-12 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,045 38 3.77 83 59.62 0.0004
2017-04-07 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,007 300 42.43 52 100.00 0.0003
2017-01-09 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 707 95 15.52 26 -36.59 0.0002
2016-10-12 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 612 542 774.29 41 925.00 0.0003
2016-07-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 70 0 0.00 4 0.00 0.0000
2016-04-08 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 70 -600 -89.55 4 -93.65 0.0000
2016-01-11 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 670 0 0.00 63 16.67 0.0005
2015-10-09 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 670 670 0.00 54 0.0005
2015-07-09 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -70 -100.00 0 -100.00
2015-04-13 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 70 70 0.00 7 0.0001
2015-01-29 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -600 -100.00 0 -100.00
2014-10-10 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 600 600 47 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.